Ibrutinib

Generic Name
Ibrutinib
Brand Names
Imbruvica
Drug Type
Small Molecule
Chemical Formula
C25H24N6O2
CAS Number
936563-96-1
Unique Ingredient Identifier
1X70OSD4VX
Background

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell ...

Indication

Ibrutinib is indicated for the treatment of the following conditions.

Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)

Waldenström's macroglobulinemia

Chronic graft-versus-host disease (cGVHD)

Mantle cell lymphoma (MCL)

Marginal zone lymphoma (MZL)

Associated Conditions
Chronic Graft-Versus-Host Disease, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma (MZL), Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Steroid-dependent chronic graft-versus-host disease, Waldenström's Macroglobulinemia (WM), Steroid refractory Chronic graft versus host disease
Associated Therapies
-

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2020-03-04
Last Posted Date
2024-07-03
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
6
Registration Number
NCT04294641
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

🇺🇸

Washington University, School of Medicine, Saint Louis, Missouri, United States

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

First Posted Date
2020-02-18
Last Posted Date
2024-08-27
Lead Sponsor
X4 Pharmaceuticals
Target Recruit Count
16
Registration Number
NCT04274738
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Mass General Hospital Cancer Center, Boston, Massachusetts, United States

🇬🇷

University of Athens, Athens, Greece

and more 2 locations

Ibrutinib + Venetoclax in Untreated WM

First Posted Date
2020-02-17
Last Posted Date
2024-04-23
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
45
Registration Number
NCT04273139
Locations
🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

First Posted Date
2020-02-10
Last Posted Date
2024-05-14
Lead Sponsor
Christian Buske
Target Recruit Count
99
Registration Number
NCT04263480
Locations
🇬🇷

Alexandra Hospital, Athens, Greece

🇩🇪

Praxis Dr. Vehling-Kaiser, Landshut, Germany

🇩🇪

Kliniken Ostalb, Staufenklinikum Schw. Gmuend, Mutlangen, Germany

and more 17 locations

Ibrutinib and Rituxan for Chronic GVHD

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2020-01-21
Last Posted Date
2024-12-13
Lead Sponsor
Northside Hospital, Inc.
Target Recruit Count
15
Registration Number
NCT04235036
Locations
🇺🇸

Northside Hospital, Atlanta, Georgia, United States

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-12-26
Last Posted Date
2024-07-23
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
23
Registration Number
NCT04212013
Locations
🇺🇸

Memorial Sloan Kettering Nassau, Uniondale, New York, United States

🇺🇸

George Washington Cancer Center, Washington, District of Columbia, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

First Posted Date
2019-12-24
Last Posted Date
2022-03-09
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
3
Registration Number
NCT04209621
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

First Posted Date
2019-10-17
Last Posted Date
2021-07-16
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
120
Registration Number
NCT04129710
Locations
🇨🇳

Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China/Zhejiang Province, China

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

First Posted Date
2019-09-18
Last Posted Date
2019-09-18
Lead Sponsor
The First Affiliated Hospital with Nanjing Medical University
Target Recruit Count
580
Registration Number
NCT04094051
Locations
🇨🇳

the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

© Copyright 2024. All Rights Reserved by MedPath